Efficacy of combination products containing sarolaner, moxidectin and pyrantel (Simparica Trio™) or afoxolaner and milbemycin (NexGard Spectra®) against induced infestations of Ixodes holocyclus in dogs

Raj Packianathan1*, Andrew Hodge1, Natalie Bruellke1, Chrissie Jackson2 and Steven Maeder1

Abstract

Background: The Australian paralysis tick, Ixodes holocyclus, causes tick paralysis in dogs and cats in the eastern coastal regions of Australia. Prevention is the best option to protect dogs against this potentially fatal disease and sarolaner provides rapid and sustained efficacy against I. holocyclus. In this laboratory study, the efficacy of two combination endectocides containing sarolaner + moxidectin + pyrantel (Simparica Trio™) and afoxolaner + milbemycin (NexGard Spectra®) was evaluated against an artificial infestation of I. holocyclus.

Methods: Twenty-four (n = 24) foxhounds were randomly allocated to three treatment groups and artificially infested with 30 adult female viable ticks on Days −1, 7, 14, 21, 28 and 35. On Day 0, dogs in each treatment group were treated with either Drontal® (control group), Simparica Trio™ at the label dose to provide minimum doses of sarolaner (1.2 mg/kg), moxidectin (24 µg/kg) and pyrantel (5 mg/kg) or NexGard Spectra® to provide minimum doses of afoxolaner (2.5 mg/kg) and milbemycin (0.5 mg/kg). Live tick counts were performed at 48 and 72 hours after treatment and after each re-infestation on Days 7, 14, 21, 28 and 35. Efficacy was determined at each time point relative to counts for control dogs based on geometric means.

Results: Against an existing infestation, efficacy of both Simparica Trio™ and NexGard Spectra® was 99.6% and 100% at 48 and 72 h time points, respectively (P = 1.000). Against subsequent weekly infestations, treatment with Simparica Trio™ and NexGard Spectra® resulted in efficacy of ≥ 97.7% and ≥ 95.5% (P ≥ 0.0911), respectively at the 48 h time point and at the 72 h time point, Simparica Trio™ and NexGard Spectra® resulted in efficacy of ≥ 99.0% and ≥ 98.4% (P ≥ 0.0511), respectively. There were no treatment-related adverse events in the study.

Conclusions: Single doses of Simparica Trio™ and NexGard Spectra® were highly efficacious and provided comparable efficacy against the Australian paralysis tick, I. holocyclus for up to 35 days.

Keywords: Isoxazoline, Ixodes holocyclus, NexGard Spectra®, Simparica Trio™

*Correspondence: raj.packianathan@zoetis.com
1 Zoetis Australia Research and Manufacturing Pty Ltd, Veterinary Medicine Research and Development, Level 6, 5 Rider Boulevard, Rhodes, NSW 2138, Australia
Full list of author information is available at the end of the article
Background

The isoxazoline class of ectoparasiticides such as sarolaner, afoxolaner, fluralaner and lotilaner are highly efficacious and have broader spectrum activity against ticks, fleas and/or mites [1–9]. The combination of the isoxazolines with one or more additional active ingredients has provided activity against other parasites, such as heartworm and gastrointestinal nematodes [10–14]. Heartworm disease caused by *Dirofilaria immitis* is endemic in Australia [15–18]. Currently, the majority of heartworm cases in dogs are reported in the tropical regions of Australia, such as Far North Queensland [19] where an abundance of heartworm reservoirs and vectors are present [20, 21]. Gastrointestinal nematode infections are one of the most common diseases in dogs and endemic throughout Australia [15, 22–25].

*Ixodes holocyclus*, also known as the Australian paralysis tick, is the major cause of tick paralysis in dogs in Australia. It is widely distributed along the eastern coastal regions of Australia from North Queensland to Lakes Entrance of Victoria [26–29]. Another ixodid tick, *Ixodes cornutus*, is also reported to cause clinically significant paralysis in some parts of south-eastern Australia [29, 30]. Clinical manifestations of tick paralysis caused by *I. holocyclus* in dogs have been well documented [31, 32]. Treatment of tick paralysis involves removal of attached ticks to prevent further envenomation and administration of tick anti-sera to neutralise the circulating free holocyclotoxins while stabilising the secondary cardio-pulmonary complications [33, 34]. Prognosis of tick paralysis cases depends on various factors such severity of clinical signs at the time of presentation, seasonality and potency of the anti-sera [31, 34]. Prevention is therefore the best option to protect dogs and cats against this fatal disease [35]. Since the introduction of isoxazolines in Australia, the incidence of tick paralysis related insurance claims appears to be declining which is a testimony to their efficacy [36].

These parasites are also zoonotic in nature and can potentially infect humans. Zoonotic diseases caused by *Toxocara canis*, *Ancylostoma caninum* and *Echinococcus granulosus* in humans are well understood [37–40]. Tick paralysis caused by *I. holocyclus* [41] and heartworm infections in humans have also been reported [42, 43]. *Ixodes holocyclus* is also suspected to act as a vector for transmission of *Borrelia burgdorferi* (sensu stricto) [44] and *Rickettsia australis* in humans [45, 46]. Hence, these combination products, with a broad spectrum of activity, not only protect dogs against these diseases, but also are important for human health thus supporting the ‘One Health paradigm’ [47, 48].

Here we report on a laboratory study to evaluate and compare the efficacy of two combination endectocides containing sarolaner + moxidectin + pyrantel (Simparica Trio™, Zoetis, Australia) and afoxolaner + milbemycin (NexGard Spectra®, Boehringer Ingelheim Animal Health, Australia) against an artificial infestation of *I. holocyclus*. Simparica Trio™ is approved in Australia for the treatment and control of fleas, ticks (*I. holocyclus* and *R. sanguineus*) and gastrointestinal worms (hookworms and roundworms) as well as the prevention of heartworm disease caused by *D. immitis* in dogs.

Sarolaner (Simparica™, Zoetis) chewable tablet dosed at 2 mg/kg body weight, a potent ecto-parasiticide, has excellent efficacy against ticks, fleas and mites [6] and has been demonstrated to provide rapid and sustained efficacy against *I. holocyclus* [49]. To broaden the spectrum of activity, a new novel oral chewable combination product delivering 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel (Simparica Trio™, Zoetis) has been approved in USA, Canada, Europe and Australia. Simparica Trio™ has been shown to be efficacious against various tick species and fleas in the USA and Europe [50–54].

Methods

This was a blinded, negative-controlled, randomised laboratory efficacy study conducted in New South Wales (NSW), Australia. Study procedures were in accordance with the World Association for the Advancement of Veterinary Parasitology (WAAVP) guidelines for evaluating the efficacy of parasiticides for the treatment, prevention and control of flea and tick infestation on dogs and cats [55] and complied with the principles of Good Clinical Practice [56]. The study was conducted according to the Australian Pesticides and Veterinary Medicines Authority (APVMA) guidelines [57]. The protocol was reviewed and approved by the Wongaburra Research Centre Animal Ethics Committee, NSW, Australia. Blinding of the study was assured through the separation of functions. All personnel conducting observations, or performing infestations and counts were blinded to treatment allocation.

Animals

Twenty-four (*n* = 24) pure and crossbred Foxhound dogs of both sexes (14 females and 10 males), aged between 3 and 8 years were enrolled in the study. Each dog was individually identified by a unique electronic transponder. All dogs had undergone an adequate wash-out period for at least 90 days to ensure that no residual ectoparasiticide efficacy remained from any previously administered treatments which was confirmed by the tick carrying capacity tests conducted on
day – 8. Dogs were individually housed in indoor runs such that no physical contact was possible between them and they were acclimatised to these conditions for at least 14 days prior to treatment. Dogs were fed an appropriate maintenance ration of a commercial dry canine feed for the duration of the study. Water was available ad libitum. All dogs were given a physical examination to ensure that they were in good health at enrolment and suitable for inclusion in the study. General health observations were performed three times daily throughout the study.

Design
The study followed a randomised complete block design, with pairs of dogs as the experimental unit. Dogs enrolled in the study were immunised to the tick toxin-holocyclotoxin as described previously [58]. Prior to treatment on Day 0, dogs were ranked according to pre-treatment tick counts into four blocks of six (three pairs of dogs). Within each block, one pair of dogs was randomly allocated to one of three treatment groups. Dogs in the control group were treated with praziquantel (175 mg) + pyrantel (174.4 mg) + febantel (875 mg) combination (Drontal® Bayer, Australia) for the control of pre-existing gastrointestinal worm burden, as per the label dose (1 tablet per 35 kg). As Drontal® does not have any acaricidal effect, this group functioned as the negative control group for the assessment of tick counts in this study. Dogs in the other two groups were treated with combination products containing either sarolaner + moxidectin + pyrantel (Simparica Trio™, Zoetis, Australia) or afoxolaner + milbemycin (NexGard Spectra®, Boehringer Ingelheim Animal Health, Australia).

Treatment
Body weights recorded on the treatment day were used to calculate the appropriate dose of each treatment and the enrolled dogs weighed between 28.7 and 42.2 kg. All dogs were fasted overnight prior to Day 0 and the first feed was offered approximately 4 h after treatment administration. Dogs received their respective treatments according to the label instructions. The dogs in the Simparica Trio™-treated group received sarolaner at minimum 1.2 mg/kg (actual doses ranged from 1.30 to 1.71 mg/kg), moxidectin at minimum 24 µg/kg (26.0–34.1 µg/kg) and pyrantel at minimum 5 mg/kg (5.42–7.11 mg/kg). The dogs in the NexGard Spectra®-treated group received afoxolaner at minimum 2.5 mg/kg (actual doses ranged between 2.61–4.63 mg/kg) and milbemycin at minimum 0.5 mg/kg (0.52–0.93 mg/kg). All doses were administered by hand pilling to ensure accurate and complete dosing. Each dog was observed for at least 2 min after treatment to ensure the dose was swallowed and for 2 h for evidence of vomiting. Vomiting was recorded only in one dog treated with Drontal® in the study. The dogs were monitored for clinical signs approximately 1, 3, 6 and 24 h post-treatment.

Tick infestation and assessment
Wild-caught, unfed adult female I. holocyclus ticks collected from Queensland and the Northern Rivers region of New South Wales, Australia were used in the study. The ticks were stored in dark conditions at around 12 °C and high humidity [58] for approximately 9 months prior to the start of the study. Prior to each infestation, dogs were examined to ensure they were free of ticks. Each dog was infested with 30 adult female unfed, viable ticks on each of Days – 1, 7, 14, 21, 28 and 35 at pre-defined locations (head, shoulders, dorsal midline of the body and tail base) on the dogs as described previously [58]. Following Day – 1 infestation, tick counts were performed at 48 and 72 h after treatment on Day 0 to evaluate the immediate efficacy of treatment and all other tick counts were performed at 48 and 72 h after each weekly infestation to evaluate the persistent efficacy. Tick assessments at 48 h time points were performed without removing the ticks from the dogs. After counting at the 72 h time point, all ticks were removed. Both free and attached ticks were characterized as either live or dead as described previously [58]. Moribund ticks were characterized and included in the live counts as previously described [49]. All the tick counts and assessments were performed by laboratory technicians who were experienced and trained on validated laboratory methods of tick counting and assessments.

Statistical analysis
The primary outcome measure was live tick counts. Data for post-treatment live (free plus attached) tick counts were summarised with arithmetic (AM) and geometric (GM) means by treatment group and time point. Tick counts were transformed by the log(count + 1) transformation prior to analysis in order to stabilise the variance and normalise the data. Using the PROC MIXED procedure (SAS 9.4, SAS Institute Inc., Cary, NC, USA), transformed counts were analysed using a mixed linear model for repeated measures for the 48 and 72 h time points separately. The fixed effects were treatment, time point and the interaction between time point and treatment. The random effects included block, pair, animal, block by treatment by time point interaction, and error. Testing was two-sided at the significance level α=0.05, with tests based on contrasts between treatment least squares means from the fitted models.
The assessment of efficacy for live ticks was based on the percent reduction in the AM and GM live tick counts for the treated groups relative to control, as suggested by the most recent guidelines of the WAAVP for systemic acaricides [35], and was calculated using Abbott’s formula:

\[
\text{% Reduction} = 100 \times \frac{\text{Mean count (control)} - \text{Mean count (treated)}}{\text{Mean count (control)}}
\]

As the distribution of parasite counts within each group was likely be skewed, comparison between groups was primarily based on GM live tick counts [55].

Results and discussion

Safety

Three dogs in the Simparica Trio™-treated group were treated for dermatitis or lick granuloma and three dogs in the NexGard Spectra®-treated group were treated for trauma, lick granuloma and/or gastrointestinal upset. None of these adverse events were considered as treatment-related.

Efficacy

Dogs in the control group maintained good tick infestations throughout the study with individual tick counts ranging from 16 to 31 and geometric mean counts between 20 to 26 (Tables 1 and 2).

Against an existing infestation, at the 48 and 72 h time points, treatment with Simparica Trio™ and NexGard Spectra® resulted in significantly lower GM tick counts compared to the control group (11.76 ≤ t_{df} ≤ 29.10 where 33 ≤ df ≤ 51, \( P < 0.0001 \)). However there were no significant differences in the GM tick counts between the two treatments at any time point (-2.00 ≤ t_{df} ≤ 1.71 where 33 ≤ df ≤ 73, \( P ≥ 0.0511 \)). Based on arithmetic mean counts, the efficacy of Simparica Trio™ and NexGard Spectra® against subsequent weekly infestations was ≥ 96.9% and ≥ 92.9%, respectively, at the 48 h time points and ≥ 97.8% for both products at the 72 h time points.

Single doses of Simparica Trio™ and NexGard Spectra® resulted in the rapid reduction of an existing infestation and subsequent re-infestations of live I. holocyclus ticks for up to 5 weeks. Although the onset of clinical signs of tick paralysis does not occur until 4 or 5 days after tick attachment, the sooner the attached ticks can be killed, the lower the chance of tick paralysis [59–61]. The rapid and sustained speed of kill of Simparica Trio™ after a single oral dose will minimise the risk of tick paralysis. Similar efficacy of Simparica Trio™ has also been demonstrated against ixodid ticks in Europe (Ixodes ricinus and Ixodes hexagonus) and the USA (Ixodes scapularis), respectively [51, 53].

Conclusions

Single doses of Simparica Trio™, containing sarolaner, moxidectin and pyrantel and NexGard Spectra® containing afoxolaner and milbemycin provided comparable efficacy against the Australian paralysis tick, I. holocyclus for up to 35 days. These two combination products with a broader spectrum of activity will provide effective control of the most important parasites in dogs including the Australian paralysis tick, fleas, heartworm, roundworms and hookworms of zoonotic significance, thus offering a holistic one health treatment option to the pet owners.
Table 1  Mean live *Ixodes holocyclus* counts and efficacy relative to control at 48 h after treatment and after weekly re-infestations for dogs treated with a single oral dose of Simparica Trio™ or NexGard Spectra® on Day 0

| Treatment                  | Day of study |           |           |           |           |           |
|----------------------------|--------------|-----------|-----------|-----------|-----------|-----------|
|                            |              | 2         | 9         | 16        | 23        | 30        | 37        |
| Control                    |              |           |           |           |           |           |           |
| Range                      | 17–27        | 16–26     | 22–31     | 20–28     | 19–29     | 18–30     |           |
| Arithmetic mean (AM)       |              | 22.13     | 20.63     | 25.38     | 24.50     | 23.50     | 22.75     |
| Geometric mean (GM)<sup>a</sup> |          | 21.92     | 20.45     | 25.26     | 24.40     | 23.31     | 22.39     |
| Simparica Trio™            |              |           |           |           |           |           |           |
| Range                      | 0–1          | 0–3       | 0–2       | 0–2       | 0–1       | 0–2       |           |
| Arithmetic mean (AM)       | 0.13         | 0.63      | 0.50      | 0.75      | 0.13      | 0.38      |           |
| Efficacy (%) AM            | 99.44        | 96.97     | 98.03     | 96.94     | 99.47     | 98.35     |           |
| Geometric mean (GM)<sup>a</sup> |          | 0.09      | 0.41      | 0.36      | 0.57      | 0.09      | 0.25      |
| Efficacy (%) GM            | 99.59        | 97.97     | 98.56     | 97.68     | 99.61     | 98.88     |           |
| Test statistic vs control  | t<sup>(51)</sup>_1 = 19.75   | t<sup>(51)</sup>_2 = 17.63 | t<sup>(51)</sup>_3 = 19.18 | t<sup>(51)</sup>_4 = 18.07 | t<sup>(51)</sup>_5 = 20.13 | t<sup>(51)</sup>_6 = 18.99 |           |
| P-value vs control         | < 0.0001     | < 0.0001  | < 0.0001  | < 0.0001  | < 0.0001  | < 0.0001  |           |
| NexGard Spectra®           |              |           |           |           |           |           |           |
| Range                      | 0–1          | 0–5       | 0–4       | 0–7       | 0–1       | 0–4       |           |
| Arithmetic mean (AM)       | 0.13         | 1.13      | 1.25      | 1.75      | 0.75      | 1.25      |           |
| Efficacy (%) AM            | 99.44        | 94.55     | 95.07     | 92.86     | 96.81     | 94.51     |           |
| Geometric mean (GM)<sup>a</sup> |          | 0.09      | 0.71      | 0.78      | 1.10      | 0.68      | 0.91      |
| Efficacy (%) GM            | 99.59        | 96.54     | 96.92     | 95.48     | 97.08     | 95.92     |           |
| Test statistic vs control  | t<sup>(45)</sup>_1 = 14.37 | t<sup>(45)</sup>_2 = 11.95 | t<sup>(45)</sup>_3 = 12.71 | t<sup>(45)</sup>_4 = 11.76 | t<sup>(45)</sup>_5 = 12.61 | t<sup>(45)</sup>_6 = 11.82 |           |
| P-value vs control         | < 0.0001     | < 0.0001  | < 0.0001  | < 0.0001  | < 0.0001  | < 0.0001  |           |
| Test statistic vs sarolaner| t<sup>(73)</sup>_1 = 0.00    | t<sup>(73)</sup>_2 = 0.74   | t<sup>(73)</sup>_3 = 1.05   | t<sup>(73)</sup>_4 = 1.17   | t<sup>(73)</sup>_5 = 1.71   | t<sup>(73)</sup>_6 = 1.68   |           |
| P-value vs sarolaner       | 1.0000       | 0.4599    | 0.2984    | 0.2461    | 0.0911    | 0.0972    |           |

*P*-values are based on comparison of geometric means
**Table 2** Mean live *Ixodes holocyclus* counts and efficacy relative to control at 72 h after treatment and after weekly re-infestations for dogs treated with a single oral dose of Simparica Trio™ or NexGard Spectra® on Day 0

| Treatment          | Day of study | Day 3 | Day 10 | Day 17 | Day 24 | Day 31 | Day 38 |
|--------------------|--------------|-------|--------|--------|--------|--------|--------|
| Control            |              | Range | 17–27  | 17–27  | 23–28  | 21–27  | 17–29  | 19–28  |
|                    |              | AM    | 21.88  | 20.88  | 24.95  | 24.18  | 22.86  | 22.94  |
|                    |              | GM    | 21.64  | 20.69  |        |        |        |        |
| Simparica Trio™    | 0–0          | 0.00  | 0.00   | 0.38   | 0.00   | 0.13   | 0.00   |
|                    | 0–0          | 100   | 100    | 98.50  | 100    | 99.46  | 100    |
|                    | 0–2          | 0.00  | 0.00   | 0.25   | 0.00   | 0.09   | 0.00   |
|                    | 0–0          | 100   | 100    | 98.99  | 100    | 99.00  | 100    |
| Test statistic vs  |              |       |        |        |        |        |        |
| control            |              |       |        |        |        |        |        |
|                    |              |       |        |        |        |        |        |
| AM Efficacy (%)    |              |       |        |        |        |        |        |
|                    |              |       |        |        |        |        |        |
| Geometric mean (GM)|              |       |        |        |        |        |        |
|                    |              |       |        |        |        |        |        |
| GM Efficacy (%)    |              |       |        |        |        |        |        |
|                    |              |       |        |        |        |        |        |
| Test statistic vs  |              |       |        |        |        |        |        |
| Simparica Trio™    |              |       |        |        |        |        |        |
| P-value vs control |              |       |        |        |        |        |        |
|                    |              |       |        |        |        |        |        |
| Test statistic vs  |              |       |        |        |        |        |        |
| NexGard Spectra®   |              |       |        |        |        |        |        |
| P-value vs control |              |       |        |        |        |        |        |

* P-values are based on comparison of geometric means

**Abbreviations**
AM: arithmetic mean; GM: geometric mean; WAAVP: World Association for the Advancement of Veterinary Parasitology.

**Acknowledgements**
The staff of Invetus Australia are gratefully acknowledged for their dedication to the study execution. Authors also would like to thank Drs John Messer and Megan Lui of Zoetis Australia Pty Ltd for reviewing this manuscript.

**Authors’ contributions**
All authors assisted with the design and conduct of the study and interpretation of the data. Manuscript was written by RP and AH. NB, CJ and SM contributed to drafting. All authors read and approved the final manuscript.

**Funding**
Funding for the design, conduct of the study and data collection was provided by Zoetis Australia Research & Manufacturing Pty Ltd.

**Availability of data and materials**
The dataset supporting the conclusions of this article is included within the article.

**Ethics approval and consent to participate**
An animal ethics approval was obtained from the Wongaburra Research Centre Animal Ethics Committee on 26 February 2018 prior to the commencement of the study. The animal ethics approval number was ZOE C 17145 W. This study did not report on any data related to humans. All dogs enrolled in the study were owned by the Invetus who conducted this study.

**Consent for publication**
Not applicable.

**Competing interests**
RP, AH, NB and SM are current employees of Zoetis. CJ was a contracted study investigator.

**Author details**
1 Zoetis Australia Research and Manufacturing Pty Ltd, Veterinary Medicine Research and Development, Level 6, 5 Rider Boulevard, Rhodes, NSW 2138, Australia. 2 Invetus, 495 Ellangowan Road, Yorklea, NSW 2470, Australia.

**Received:** 3 May 2020  **Accepted:** 30 August 2020

**Published online:** 05 September 2020

**References**
1. Beugnet F, de Vos C, Liebenberg J, Halos L, Larsen D, Fournie J. Efficacy of afoxolaner in a clinical field study in dogs naturally infested with *Sarcoptes scabiei*. Parasite. 2016;23:26.
2. Becskei C, De Bock F, Illambas J, Cherni JA, Fournie JJ, Lane M, et al. Efficacy and safety of a novel oral isoxazoline, sarolaner (Simparica™), for the treatment of sarcoptic mange in dogs. Vet Parasitol. 2016;222:56–61.
3. Lebon W, Beccati M, Bourdeau P, Brement T, Bruet V, Cekiera A, et al. Efficacy of two formulations of afoxolaner (NexGard™ and NexGard Spectra®) for the treatment of generalised demodicosis in dogs, in veterinary dermatology referral centers in Europe. Parasit Vectors. 2018;11:506.
4. Six RH, Becskei C, Mazaleski MM, Fournie JJ, Mahabir SP, Myers MR, et al. Efficacy of sarolaner, a novel oral isoxazoline, against two common mite infestations in dogs: Demodex spp and Otodectes cynotis. Vet Parasitol. 2016;222:62–6.

5. Taender J, Liebenberg J, Roepke RKA, Frénais R, Heckerth OR. Efficacy of fluralaner administered either orally or topically for the treatment of naturally acquired Sarcoptes scabiei var canis infestation in dogs. Parasit Vectors. 2016;9:392.

6. McTier TL, Chubb N, Curtis MP, Hedges L, Inskhip GA, Kauner CS, et al. Discovery of sarolaner: A novel, orally administered, broad-spectrum, isoxazoline ectoparasiticide for dogs. Vet Parasitol. 2016;222:3–11.

7. Shoop WL, Hartline EJ, Gould BR, Waddell MD, Seewald W, Drake J. Laboratory evaluations of the immediate and sustained effectiveness of lotilaner (Credelio™) against three common species of ticks affecting dogs in Europe. Parasit Vectors. 2017;10:527.

8. Gassel M, Wolf C, Noack S, Williams H, Ilg G, Wolf C, et al. The novel isoxazoline ectoparasiticide fluralaner: Selective inhibition of arthropod γ-aminobutyric acid- and L-glutamate-gated chloride channels and insecticidal/accidarial activity. Insect Biochem Mol Biol. 2014;45:11–24.

9. Cavaliere D, Murphy M, Giorba RL, Seewald W, Drake J. Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs. Parasit Vectors. 2019;12:445.

10. Becskei C, Kryda K, Six RH, Walsh SF, Holzmer SJ, Chapin S, Mahabir SP, et al. Field efficacy and safety of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against naturally acquired gastrointestinal nematode infections in dogs presented as veterinary patients in Europe and the USA. Parasit Vectors. 2020;13:70.

11. Becskei C, Kryda K, Fias D, Follis SL, Wozniakiewicz M, Mahabir SP, et al. Field efficacy of oral sarolaner tablet containing moxidectin, sarolaner, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs. Parasit Vectors. 2019;12:911–27.

12. Banerjee C, Becskei C, Kryda K, Fias D, Follis SL, Wozniakiewicz M, Mahabir SP, et al. Field efficacy and safety of a novel, orally administered combination product containing moxidectin, sarolaner, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs. Parasit Vectors. 2019;12:445.

13. Morgan A. The role of ticks in the transmission of heartworm (Dirofilaria immitis) in dogs. J Vet Sci. 2014;15:919–21.

14. Tong J, Frewin L, Chung S, Grey TD, Gaskell M. The life cycle of Dirofilaria immitis and its implications for heartworm prevention. Parasit Vectors. 2016;9:399.

15. Baxt W, Lin J, Zekry T, Elghalibi A, Elghalibi A, et al. Efficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) in dogs against hookworm infections. Vet Parasitol. 2019;291:108439.

16. Zekry T, Baxt W, Elghalibi A, Elghalibi A, et al. Efficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel against hookworm infections in dogs. Parasit Vectors. 2020;13:99.

17. Zekry T, Baxt W, Elghalibi A, Elghalibi A, et al. Efficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel against hookworm infections in dogs. Parasit Vectors. 2020;13:99.

18. Zekry T, Baxt W, Elghalibi A, Elghalibi A, et al. Efficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel against hookworm infections in dogs. Parasit Vectors. 2020;13:99.

19. Zekry T, Baxt W, Elghalibi A, Elghalibi A, et al. Efficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel against hookworm infections in dogs. Parasit Vectors. 2020;13:99.

20. Zekry T, Baxt W, Elghalibi A, Elghalibi A, et al. Efficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel against hookworm infections in dogs. Parasit Vectors. 2020;13:99.

21. Zekry T, Baxt W, Elghalibi A, Elghalibi A, et al. Efficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel against hookworm infections in dogs. Parasit Vectors. 2020;13:99.

22. Zekry T, Baxt W, Elghalibi A, Elghalibi A, et al. Efficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel against hookworm infections in dogs. Parasit Vectors. 2020;13:99.
49. Packianathan R, Hodge A, Bruellke N, Davis K, Maeder S. Comparative speed of kill of sarolaner (Simparica®) and afoxolaner (NexGard®) against induced infestations of Ixodes holocyclus on dogs. Parasit Vectors. 2017;10:98.

50. Becskei C, Fias D, Mahabir SP, Farkas R. Efficacy of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against natural flea and tick infestations on dogs presented as veterinary patients in Europe. Parasit Vectors. 2020;13:72.

51. Becskei C, Liebenberg J, Thys M, Mahabir SP. Efficacy of a novel chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against four common tick species infesting dogs in Europe. Parasit Vectors. 2020;13:100.

52. Kryda K, Mahabir SP, Carter L, Everett WR, Young DR, Meyer L, et al. Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs. Parasit Vectors. 2020;13:57.

53. Kryda K, Mahabir SP, Chapin S, Holzmer SJ, Bowersock L, Everett WR, et al. Efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced infestations of five common tick species infesting dogs in the USA. Parasit Vectors. 2020;13:77.

54. Kryda K, Mahabir SP, Insktke T, Rugg J. Safety and efficacy of a novel oral chewable combination tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against natural flea infestations in client-owned dogs in the USA. Parasit Vectors. 2020;13:98.

55. Marchiondo AA, Holdsworth PA, Foureille L, Rugg D, Kellmann K, Snyder DE. World Association for the Advancement of Veterinary Parasitology (WAAVP) second edition: guidelines for evaluating the efficacy of parasitcides for the treatment, prevention and control of flea and tick infestations on dogs and cats. Vet Parasitol. 2013;194:84–97.

56. EMEA. Guideline on good clinical practices. VICH Topic GL9 2001. https://vichsec.org/en/guidelines/pharmaceuticals/pharma-efficacy/good-clinical-practice.html. Accessed 23 May 2020.

57. Australian Pesticides and Veterinary Medicines Authority (APVMA). The WAAVP guideline for fleas and ticks on dogs and cats. https://apvma.gov.au/node/1040. 2019.

58. Fisara P, Webster M. A randomized controlled trial of the efficacy of orally administered fluralaner (Bravecto) against induced Ixodes holocyclus (Australian paralysis tick) infestations on dogs. Parasit Vectors. 2015;8:257.

59. Ilkiw JE, Turner DM, Howlett CR. Infestation of the dog by the paralysis tick Ixodes holocyclus. 1. Clinical and histological findings. Aust Vet J. 1987;64:137–9.

60. Ross IC. Tick paralysis in the dog. Aust Vet J. 1934;10:182–3.

61. Ross IC. An experimental study of tick paralysis in Australia. Aust Vet J. 1927;4:310–29.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.